Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.34 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8065592 | 0.76 | FOLH1 (0.50) | FOLH1ALDH1A1GRM3NAALAD2 | |
| SCHEMBL5051235 | 0.75 | GRM3 (0.56) | FOLH1ALDH1A1GRM3NAALAD2 | |
| SCHEMBL8427855 | 0.73 | ALDH1A1 (0.40) | FOLH1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29191695 | 0.72 | GRIK1 (0.43) | SMN1; SMN2 | |
| SCHEMBL6037781 | 0.72 | FOLH1 (0.50) | FOLH1ALDH1A1GRM3NAALAD2 | |
| SCHEMBL5051129 | 0.69 | GRM3 (0.55) | FOLH1ALDH1A1GRM3NAALAD2 | |
| SCHEMBL5058034 | 0.69 | GRM3 (0.51) | FOLH1GRM3NAALAD2 | |
| SCHEMBL5060671 | 0.68 | FOLH1 (0.37) | FOLH1 | |
| SCHEMBL8653950 | 0.68 | FOLH1 (0.66) | FOLH1ALDH1A1 | |
| SCHEMBL1373543 | 0.67 | FOLH1 (0.51) | FOLH1GRM3NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0994707-A4 | INHIBITORS OF NAALADASE ENZYME ACTIVITY | GUILFORD PHARM INC (US) | 2001-11-14 | — | — | EP | claimed |
| EP-0994707-A1 | INHIBITORS OF NAALADASE ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 2000-04-26 | — | — | EP | claimed |
| WO-1998053812-A1 | INHIBITORS OF NAALADASE ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 1998-12-03 | — | — | WO | claimed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
| EP-0994707-A4 | INHIBITORS OF NAALADASE ENZYME ACTIVITY | GUILFORD PHARM INC (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-0994707-A1 | INHIBITORS OF NAALADASE ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 2000-04-26 | — | — | EP | disclosed |
| US-6025345-A | NOVEL PHOSPHONATE DERIVATIVES, HYDROXYPHOSPHINYL DERIVATIVES, AND PHOSPHORAMIDATE DERIVATIVES THAT INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY, | GUILFORD PHARMACEUTICALS INC. (US) | 2000-02-15 | — | — | US | disclosed |
| WO-1998053812-A1 | INHIBITORS OF NAALADASE ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | FOLH1 1/4885ALDH1A1 257/4885GRM3 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.